CASTLE BIOSCIENCES INC (CSTL) Form 8-K — Jul 30, 2026

$CSTLForm 8-KItems 2.02, 7.01, 9.01Filed Jul 30, 2026, 4:06 PM ET0001628280-26-051045Original filing

Castle Biosciences reported second quarter 2026 revenue of $103.5 million, an increase from $86.2 million in the prior year, driven by a 32% rise in test reports for core products DecisionDx-Melanoma and TissueCypher. Based on this momentum, the company raised its full-year 2026 revenue guidance to $365-375 million, up from the previous range of $345-355 million, and now expects to achieve positive Adjusted EBITDA for the third quarter, the fourth quarter, and the full year.

Key figures

Eps: -0.07
Revenue: 103.5 million
Guidance: $365-375 million
Net Income: -2.1 million
Cash Position: $266.8 million
Gross Margin: 75%
Adjusted Ebitda: 12.4 million

Price after filing

1 day: +2.4%7 days: +27.5%30 days: +40.2%

Close on the filing date to close N calendar days later (from $23.89). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.